146 related articles for article (PubMed ID: 33762827)
1. Lack of Synergy Between β-Agonist Treatment and a Blockage of Sarcoplasmic Calcium Flow in a Rat Cancer Cachexia Model.
Busquets S; Castillejo M; Jové Q; Jude B; Mejías P; López-Soriano FJ; Argilés JM
Onco Targets Ther; 2021; 14():1953-1959. PubMed ID: 33762827
[TBL] [Abstract][Full Text] [Related]
2. Effects of the beta
Salazar-Degracia A; Busquets S; Argilés JM; Bargalló-Gispert N; López-Soriano FJ; Barreiro E
Biochimie; 2018 Jun; 149():79-91. PubMed ID: 29654866
[TBL] [Abstract][Full Text] [Related]
3. Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist.
Toledo M; Busquets S; Penna F; Zhou X; Marmonti E; Betancourt A; Massa D; López-Soriano FJ; Han HQ; Argilés JM
Int J Cancer; 2016 Apr; 138(8):2021-9. PubMed ID: 26595367
[TBL] [Abstract][Full Text] [Related]
4. Formoterol in the treatment of experimental cancer cachexia: effects on heart function.
Toledo M; Springer J; Busquets S; Tschirner A; López-Soriano FJ; Anker SD; Argilés JM
J Cachexia Sarcopenia Muscle; 2014 Dec; 5(4):315-20. PubMed ID: 25167857
[TBL] [Abstract][Full Text] [Related]
5. Formoterol fumarate and roxithromycin effects on muscle mass in an animal model of cancer cachexia.
Kenley RA; Denissenko MF; Mullin RJ; Story J; Ekblom J
Oncol Rep; 2008 May; 19(5):1113-21. PubMed ID: 18425366
[TBL] [Abstract][Full Text] [Related]
6. Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats.
Busquets S; Toledo M; Marmonti E; Orpí M; Capdevila E; Betancourt A; López-Soriano FJ; Argilés JM
Oncol Lett; 2012 Jan; 3(1):185-189. PubMed ID: 22740878
[TBL] [Abstract][Full Text] [Related]
7. Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity.
Busquets S; Toledo M; Sirisi S; Orpí M; Serpe R; Coutinho J; Martínez R; Argilés JM; López-Soriano FJ
Exp Ther Med; 2011 Jul; 2(4):731-735. PubMed ID: 22977567
[TBL] [Abstract][Full Text] [Related]
8. Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice.
van Norren K; Kegler D; Argilés JM; Luiking Y; Gorselink M; Laviano A; Arts K; Faber J; Jansen H; van der Beek EM; van Helvoort A
Br J Cancer; 2009 Mar; 100(5):713-22. PubMed ID: 19259092
[TBL] [Abstract][Full Text] [Related]
9. Formoterol attenuates increased oxidative stress and myosin protein loss in respiratory and limb muscles of cancer cachectic rats.
Salazar-Degracia A; Busquets S; Argilés JM; López-Soriano FJ; Barreiro E
PeerJ; 2017; 5():e4109. PubMed ID: 29255650
[TBL] [Abstract][Full Text] [Related]
10. Formoterol decreases muscle wasting as well as inflammation in the rat model of rheumatoid arthritis.
Gómez-SanMiguel AB; Gomez-Moreira C; Nieto-Bona MP; Fernández-Galaz C; Villanúa MÁ; Martín AI; López-Calderón A
Am J Physiol Endocrinol Metab; 2016 Jun; 310(11):E925-37. PubMed ID: 27245339
[TBL] [Abstract][Full Text] [Related]
11. A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy.
Toledo M; Penna F; Oliva F; Luque M; Betancourt A; Marmonti E; López-Soriano FJ; Argilés JM; Busquets S
J Cachexia Sarcopenia Muscle; 2016 Mar; 7(1):48-59. PubMed ID: 27066318
[TBL] [Abstract][Full Text] [Related]
12. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
Busquets S; Figueras MT; Fuster G; Almendro V; Moore-Carrasco R; Ametller E; Argilés JM; López-Soriano FJ
Cancer Res; 2004 Sep; 64(18):6725-31. PubMed ID: 15374990
[TBL] [Abstract][Full Text] [Related]
13. β
Scholpa NE; Simmons EC; Tilley DG; Schnellmann RG
Exp Neurol; 2019 Dec; 322():113064. PubMed ID: 31525347
[TBL] [Abstract][Full Text] [Related]
14. Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors.
Fruen BR; Mickelson JR; Louis CF
J Biol Chem; 1997 Oct; 272(43):26965-71. PubMed ID: 9341133
[TBL] [Abstract][Full Text] [Related]
15. Characterization of cachexia in the human fibrosarcoma HT-1080 mouse tumour model.
Bernardo B; Joaquim S; Garren J; Boucher M; Houle C; LaCarubba B; Qiao S; Wu Z; Esquejo RM; Peloquin M; Kim H; Breen DM
J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1813-1829. PubMed ID: 32924335
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy.
Greig CA; Johns N; Gray C; MacDonald A; Stephens NA; Skipworth RJ; Fallon M; Wall L; Fox GM; Fearon KC
Support Care Cancer; 2014 May; 22(5):1269-75. PubMed ID: 24389826
[TBL] [Abstract][Full Text] [Related]
17. Serum metabolic profiles reveal the effect of formoterol on cachexia in tumor-bearing mice.
Quanjun Y; Genjin Y; Lili W; Bin L; Jin L; Qi Y; Yan L; Yonglong H; Cheng G; Junping Z
Mol Biosyst; 2013 Dec; 9(12):3015-25. PubMed ID: 24056883
[TBL] [Abstract][Full Text] [Related]
18. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity.
Zhao F; Li P; Chen SR; Louis CF; Fruen BR
J Biol Chem; 2001 Apr; 276(17):13810-6. PubMed ID: 11278295
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological Characterization of a Novel 5-Hydroxybenzothiazolone-Derived
Koziczak-Holbro M; Rigel DF; Dumotier B; Sykes DA; Tsao J; Nguyen NH; Bösch J; Jourdain M; Flotte L; Adachi Y; Kiffe M; Azria M; Fairhurst RA; Charlton SJ; Richardson BP; Lach-Trifilieff E; Glass DJ; Ullrich T; Hatakeyama S
J Pharmacol Exp Ther; 2019 May; 369(2):188-199. PubMed ID: 30819762
[TBL] [Abstract][Full Text] [Related]
20. Identification of dantrolene binding sites in porcine skeletal muscle sarcoplasmic reticulum.
Parness J; Palnitkar SS
J Biol Chem; 1995 Aug; 270(31):18465-72. PubMed ID: 7629173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
